3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Gynecologic
1
Conditions
Ovarian Neoplasms
29
Neoplasms
14
Breast Neoplasms
8
Fallopian Tube Neoplasms
7
Prostatic Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Melanoma
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Diseases
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Osteosarcoma
1
Neuroblastoma
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Interventions
pembrolizumab
75
Carboplatin
46
Paclitaxel
44
130-nm albumin-bound paclitaxel
35
Gemcitabine
34
Cyclophosphamide
23
Capecitabine
22
Nivolumab
21
Albumin-Bound Paclitaxel
21
atezolizumab
20
sacituzumab govitecan
14
spartalizumab
13
Doxorubicin
11
olaparib
9
Cisplatin
9
Bevacizumab
9
eribulin
8
fludarabine
7
durvalumab
7
avelumab
7
Injections
7
Fulvestrant
7
Fluorouracil
7
Vinorelbine
6
Leucovorin
6
Docetaxel
6
iniparib
5
budigalimab
5
Ipilimumab
5
Epirubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Breast Neoplasms
×
niraparib
×
Clear all
NCT04915755
2025-07-16
ZEST
GlaxoSmithKline
Phase 3
Active not recruiting
40 enrolled
13 charts
NCT02657889
2022-12-01
TOPACIO
Tesaro, Inc.
Phase 1/2
Completed
122 enrolled
29 charts